Beijing Tong Ren Tang Chinese Medicine Company Limited (TONGRENTANGCM) reported a notable contraction in top-line performance for the six months ended 30 June 2026, while maintaining robust liquidity and posting an improved gross margin.
Financial Highlights (YoY) • Revenue: HK$601.89 million, down 21.0% from HK$761.74 million. • Gross profit: HK$384.68 million, down 16.9%; gross margin rose to 63.9% (1H25: 60.8%) on product-mix optimisation and tighter cost control. • Profit before tax: HK$233.43 million, down 19.4%. • Profit for the period: HK$201.19 million, down 18.2%. • Profit attributable to shareholders: HK$198.20 million, down 15.6%. • Basic EPS: HK$0.24 (1H25: HK$0.28). • No interim dividend proposed (unchanged YoY).
Balance-Sheet and Cash Flow • Cash and bank balances stood at HK$2.21 billion, a 3.1% decline from end-2025. • Net assets totalled HK$4.24 billion (-3.0% vs 31 Dec 2025). • Current ratio improved to 21.0 (31 Dec 2025: 19.7); gearing remained low at 3.0%. • Net operating cash inflow reached HK$272.91 million; capex was restrained at HK$2.60 million (1H25: HK$16.40 million).
Operational Performance • Wholesale revenue from proprietary products fell 27.8% after deliberate channel tightening and price-control measures in Hong Kong, Macao and mainland China. • Hong Kong retail sales rose about 5% on enhanced promotions, staff training and incentive adjustments. • Inventory declined further as the Group sharpened its focus on core operations.
Product & Market Development • New launches: Ganoderma Liver Detox Pro (liver-care), Antelope Horn Powder Capsules (first of its kind approved in Hong Kong) and Gum Careluxe Toothpaste, reinforcing positions in macro-health and oral-care niches. • Marketing push: “Look for the Double Dragon Mark” roadshows in Hong Kong to lift Angong Niuhuang Wan sales; expanded omnichannel presence via JD Worldwide, Tmall Global, Douyin Global Shopping and own mini-programme. • International progress: Hong Kong Tai Po plant secured Vietnamese GMP certification, paving the way for Angong Niuhuang Wan entry into Vietnam. Memoranda of understanding signed with Vietnam’s Xuan Cau Holdings and Russia’s IRIMIS Limited to explore registration, distribution and e-commerce cooperation. First-ever Argentine bezoar import completed after obtaining Beijing Customs permit; South American representative office opened in Uruguay.
Strategic Priorities for 2H26 Management targets: 1. Deepen the “2+2+N” product strategy—two core pillars (Angong Niuhuang Wan, Ganoderma spores), two functional segments (medicine-food and medicine-cosmetics), plus a pipeline of innovative products. 2. Accelerate overseas product registration, with focus on ASEAN markets post-Vietnam GMP milestone. 3. Standardise and revitalise Hong Kong retail network under a “3 + 1” store upgrade plan. 4. Enhance global supply-chain resilience and ensure secure sourcing of rare medicinal materials. 5. Scale up imports of core raw ingredients through expanded overseas procurement. 6. Advance “AI + TCM” initiatives to digitalise diagnostic methods and bolster evidence-based research.
Outlook Despite headwinds from geopolitical tensions and soft demand in the Chinese medicine retail segment, TONGRENTANGCM maintains a solid cash position and low leverage, positioning the Group to pursue product innovation, channel optimisation and international expansion in the second half of 2026.